Generate Biomedicines (GENB) Registration Filing summary

Company overview and business model

• Engages in the development and commercialization of biomedicines, leveraging proprietary technology and strategic collaborations.

• Operates through licensing, manufacturing, and research agreements with leading industry partners and service providers.

• Holds exclusive and non-exclusive licenses for foundational and new intellectual property in human therapeutics and vaccines.

• Expands capabilities through acquisition of related entities and integration of collaborative R&D assets.

Financial performance and metrics

• Financial statements for acquired entities are prepared in accordance with US GAAP and reflect no outstanding debt or material liabilities at closing.

• Net sales payments and royalties are structured based on product sales, with detailed reporting and audit rights.

Use of proceeds and capital allocation

• Proceeds from the offering and business transactions are allocated to R&D, commercialization, and milestone payments under licensing and manufacturing agreements.

• Capital is also used for milestone and royalty payments to licensors and partners, as well as for manufacturing scale-up.